Warning! GuruFocus detected
1 Severe warning sign
with ABIO.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Current and historical daily PE Ratio for ARCA biopharma Inc (
) from 1997 to May 16 2025. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. ARCA biopharma stock (ABIO) PE ratio as of May 16 2025 is 0.
More Details
ARCA biopharma Inc (ABIO) PE Ratio (TTM) Chart
ARCA biopharma Inc (ABIO) PE Ratio (TTM) Historical Data
View and export this data going back to 1997. Start your Free Trial
Total 1052
- 1
- 2
- 3
- 4
- 5
- 6
- 12
ARCA biopharma PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2025-05-16 | At Loss | 2024-06-28 | At Loss |
2024-08-30 | At Loss | 2024-06-27 | At Loss |
2024-08-29 | At Loss | 2024-06-26 | At Loss |
2024-08-28 | At Loss | 2024-06-25 | At Loss |
2024-08-27 | At Loss | 2024-06-24 | At Loss |
2024-08-26 | At Loss | 2024-06-21 | At Loss |
2024-08-23 | At Loss | 2024-06-20 | At Loss |
2024-08-22 | At Loss | 2024-06-18 | At Loss |
2024-08-21 | At Loss | 2024-06-17 | At Loss |
2024-08-20 | At Loss | 2024-06-14 | At Loss |
2024-08-19 | At Loss | 2024-06-13 | At Loss |
2024-08-16 | At Loss | 2024-06-12 | At Loss |
2024-08-15 | At Loss | 2024-06-11 | At Loss |
2024-08-14 | At Loss | 2024-06-10 | At Loss |
2024-08-13 | At Loss | 2024-06-07 | At Loss |
2024-08-12 | At Loss | 2024-06-06 | At Loss |
2024-08-09 | At Loss | 2024-06-05 | At Loss |
2024-08-08 | At Loss | 2024-06-04 | At Loss |
2024-08-07 | At Loss | 2024-06-03 | At Loss |
2024-08-06 | At Loss | 2024-05-31 | At Loss |
2024-08-05 | At Loss | 2024-05-30 | At Loss |
2024-08-02 | At Loss | 2024-05-29 | At Loss |
2024-08-01 | At Loss | 2024-05-28 | At Loss |
2024-07-31 | At Loss | 2024-05-24 | At Loss |
2024-07-30 | At Loss | 2024-05-23 | At Loss |
2024-07-29 | At Loss | 2024-05-22 | At Loss |
2024-07-26 | At Loss | 2024-05-21 | At Loss |
2024-07-25 | At Loss | 2024-05-20 | At Loss |
2024-07-24 | At Loss | 2024-05-17 | At Loss |
2024-07-23 | At Loss | 2024-05-16 | At Loss |
2024-07-22 | At Loss | 2024-05-15 | At Loss |
2024-07-19 | At Loss | 2024-05-14 | At Loss |
2024-07-18 | At Loss | 2024-05-13 | At Loss |
2024-07-17 | At Loss | 2024-05-10 | At Loss |
2024-07-16 | At Loss | 2024-05-09 | At Loss |
2024-07-15 | At Loss | 2024-05-08 | At Loss |
2024-07-12 | At Loss | 2024-05-07 | At Loss |
2024-07-11 | At Loss | 2024-05-06 | At Loss |
2024-07-10 | At Loss | 2024-05-03 | At Loss |
2024-07-09 | At Loss | 2024-05-02 | At Loss |
2024-07-08 | At Loss | 2024-05-01 | At Loss |
2024-07-05 | At Loss | 2024-04-30 | At Loss |
2024-07-03 | At Loss | 2024-04-29 | At Loss |
2024-07-02 | At Loss | 2024-04-26 | At Loss |
2024-07-01 | At Loss | 2024-04-25 | At Loss |
ARCA biopharma Inc (ABIO) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
ARCA biopharma Inc
NAICS : 325413
SIC : 2835
ISIN : US00211Y4070
Description
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.